MedTrace Logo

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

NCT04740996 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-02-07

No results posted yet for this study

Summary

This trial is main evaluate the efficacy and safety of pembrolizumab in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥20.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.

Sponsors & Collaborators

  • Shi Yuankai

    lead UNKNOWN

Principal Investigators

  • Yuankai Shi, MD · Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-04
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740996 on ClinicalTrials.gov